Horizon Therapeutics plc: New Analysis Finds UPLIZNA (inebil

-- Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation

Related Keywords

United States , Ireland , American , Kristina Patterson , Neuroimmunol Neuroinflamm , Tina Ventura , Bruce Cree , Ray Gordon , Rachel Vann , Instagram , Product Communications , Linkedin , Twitter , Nasdaq , Exchange Commission , American Academy Of Neurology , Facebook , American Academy , Seattle April , Expanded Disability Status Scale , California San Francisco Weill Institute , Neuromyelitis Optica Spectrum Disorder , Progressive Multifocal Leukoencephalopathy , Prescribing Information , United States Securities , Accessed April , Scler Relat , Vice President , Chief Investor Relations Officer , Media Contact , Horizon , Herapeutics , Analysis , Kinds , Plizna , Inebilizumab , Don , Ffective , People , Ewly , Resenting , Euromyelitis , Voptica , Spectrum , Disorder , Nmosd ,